Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN4 | O15554 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CES1 | P23141 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.33 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL519210 | 0.82 | KCNN4 (0.38) | KCNN4CYP1A2ALDH1A1ALOX15CYP2C19 | |
| SCHEMBL5048108 | 0.78 | TSHR (0.39) | ALDH1A1MAPTKMT2ACES1TSHR | |
| SCHEMBL9210109 | 0.78 | CYP2C19 (0.44) | KCNN4CYP1A2ALDH1A1ALOX15CYP2C19 | |
| SCHEMBL183489 | 0.76 | KIF11 (0.40) | KCNN4CYP1A2ALDH1A1ALOX15CYP2C19 | |
| SCHEMBL11110723 | 0.74 | MAPK1 (0.36) | KCNN4CYP1A2ALDH1A1ALOX15CYP2C19 | |
| SCHEMBL9207734 | 0.74 | KCNN4 (0.36) | KCNN4CYP1A2ALDH1A1ALOX15CYP2C19 | |
| SCHEMBL135667 | 0.73 | MAPK1 (0.56) | KCNN4ALDH1A1ALOX15CYP2C19MAPK1 | |
| SCHEMBL131978 | 0.73 | MAPK1 (0.44) | KCNN4ALDH1A1ALOX15CYP2C19MAPK1 | |
| SCHEMBL1683185 | 0.73 | TSHR (0.44) | KCNN4CYP1A2ALDH1A1ALOX15PTPN1 | |
| SCHEMBL4375758 | 0.72 | ALDH1A1 (0.44) | KCNN4CYP1A2ALDH1A1ALOX15CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1054893-B1 | SYNTHETIC POLYMERS AND METHODS, KITS OR COMPOSITIONS FOR MODULATING THE SOLUBILITY OF SAME | BOSTON PROBES INC (US) | 2007-03-14 | — | — | EP | claimed |
| US-20040102571-A1 | METHODS FOR MODULATING THE SOLUBILITY OF SYNTHETIC POLYMERS | APPLIED BIOSYSTEMS, LLC | 2004-05-27 | — | — | US | claimed |
| EP-1054893-A1 | SYNTHETIC POLYMERS AND METHODS, KITS OR COMPOSITIONS FOR MODULATING THE SOLUBILITY OF SAME | Boston Probes, Inc. (US) | 2000-11-29 | — | — | EP | claimed |
| WO-1999037670-A1 | SYNTHETIC POLYMERS AND METHODS, KITS OR COMPOSITIONS FOR MODULATING THE SOLUBILITY OF SAME | BOSTON PROBES, INC. (US) | 1999-07-29 | — | — | WO | claimed |
| EP-0053538-B1 | VINYL-3 CEPHALOSPORIN DERIVATIVES AND THEIR PREPARATION | RHONE-POULENC SANTE (FR) | 1986-03-12 | — | — | EP | claimed |
| US-20210171437-A1 | PEPTIDE NUCLEIC ACID (PNA) MONOMERS WITH AN ORTHOGONALLY PROTECTED ESTER MOIETY AND NOVEL INTERMEDIATES AND METHODS RELATED THERETO | VERA THERAPEUTICS INC (US) | 2021-06-10 | — | — | US | disclosed |
| EP-3655388-A1 | PEPTIDE NUCLEIC ACID (PNA) MONOMERS WITH AN ORTHOGONALLY PROTECTED ESTER MOIETY AND NOVEL INTERMEDIATES AND METHODS RELATED THERETO | Trucode Gene Repair, Inc. (US) | 2020-05-27 | — | — | EP | disclosed |
| US-20190055190-A1 | PEPTIDE NUCLEIC ACID (PNA) MONOMERS WITH AN ORTHOGONALLY PROTECTED ESTER MOIETY AND NOVEL INTERMEDIATES AND METHODS RELATED THERETO | NEUBASE THERAPEUTICS, INC. | 2019-02-21 | — | — | US | disclosed |
| WO-2019018422-A1 | PEPTIDE NUCLEIC ACID (PNA) MONOMERS WITH AN ORTHOGONALLY PROTECTED ESTER MOIETY AND NOVEL INTERMEDIATES AND METHODS RELATED THERETO | TRUCODE GENE REPAIR, INC. (US) | 2019-01-24 | — | — | WO | disclosed |
| US-7884053-B2 | Methods, kits and compositions pertaining to combination oligomers and libraries for their preparation | BOSTON PROBES, INC. (US) | 2011-02-08 | — | — | US | disclosed |
| EP-1748078-B1 | Methods, kits and compositions of combination oligomers | BOSTON PROBES INC (US) | 2011-01-19 | — | — | EP | disclosed |
| US-7851155-B2 | Methods, kits and compositions pertaining to combination oligomers and libraries for their preparation | BOSTON PROBES, INC. (US) | 2010-12-14 | — | — | US | disclosed |
| US-5602275-A | MAY BE USED TO ACCELERATE RECOVERY FROM NEUTROPENIA ACCOMPANYING RADIO- OR CHEMOTHERAPY, BONE MARROW TRANSPLANTATION OR INFECTIONS | AMERICAN CYANAMID COMPANY (US) | 1997-02-11 | — | — | US | disclosed |
| WO-1996040685-A1 | IMPROVED SYNTHONS FOR THE SYNTHESIS AND DEPROTECTION OF PEPTIDE NUCLEIC ACIDS UNDER MILD CONDITIONS | PERSEPTIVE BIOSYSTEMS, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
| EP-0652228-B1 | Urethanes and ureas that induce cytokine production | AMERICAN CYANAMID CO (US) | 1996-10-23 | — | — | EP | disclosed |
| US-5545662-A | USED TO ACCELERATE RECOVERY FROM NEUTROPENIA ACCOMPANYING RADIO OR CHEMOTHERAPY, BONE MARROW TRANSPLANTATION, OR INFECTIONS | AMERICAN CYANAMID COMPANY (US) | 1996-08-13 | — | — | US | disclosed |
| EP-0652228-A1 | Urethanes and ureas that induce cytokine production | AMERICAN CYANAMID COMPANY (US) | 1995-05-10 | — | — | EP | disclosed |
| US-5312831-A | Immunology, anticarcinogenic agents and AIDS treatment | AMERICAN CYANAMID COMPANY (US) | 1994-05-17 | — | — | US | disclosed |
| EP-0027260-B1 | PEPTIDES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1985-03-13 | — | — | EP | disclosed |
| US-4089955-A | ANTIBIOTICS | CIBA-GEIGY CORPORATION (US) | 1978-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190055190-A1 | PEPTIDE NUCLEIC ACID (PNA) MONOMERS WITH AN ORTHOGONALLY PROTECTED ESTER MOIETY AND NOVEL INTERMEDIATES AND METHODS RELATED THERETO | TARBP1, TIA1, SSB | KCNN4 4451/4885CYP1A2 4778/4885ALDH1A1 4569/4885 |
| US-20210171437-A1 | PEPTIDE NUCLEIC ACID (PNA) MONOMERS WITH AN ORTHOGONALLY PROTECTED ESTER MOIETY AND NOVEL INTERMEDIATES AND METHODS RELATED THERETO | TARBP1, TIA1, SSB | KCNN4 4451/4885CYP1A2 4778/4885ALDH1A1 4569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.